Table 1 Baseline characteristics of HCC patients receiving anti-PD-1 blockades
From: Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
Characteristics | Number (%) |
|---|---|
Sample size | 235 |
Age, years | |
  ≤ 50 | 109 (46.4) |
 >50 | 126 (53.6) |
Chronic liver disease | |
 HBV | 203 (86.4) |
 None | 32 (13.6) |
Gender | |
 Female | 31 (13.2) |
 Male | 204 (86.8) |
Vascular invasion | |
 No | 113 (48.1) |
 Yes | 122 (51.9) |
Extrahepatic metastasis | |
 No | 148 (63.0) |
 Yes | 87 (37.0) |
ALBI grade | |
 I | 142 (60.4) |
 II | 93 (39.6) |
AFP reduction> 50% | |
 No | 122 (51.9) |
 Yes | 113 (48.1) |
PIVKA-II reduction> 50% | |
 No | 110 (46.8) |
 Yes | 125 (53.2) |
Baseline AFP level, ng/ml | |
 Median (range) | 2995.0 (25.14–121,000) |
  ≤ 400 | 78 (33.2) |
  > 400 | 157 (66.8) |
Baseline PIVKA-II level, mAU/ml | |
 Median (range) | 7209.0 (41–75,000) |
  ≤ 400 | 44 (18.7) |
  > 400 | 191 (81.3) |